A dynamic COVID-19 immune signature includes associations with poor prognosis.

Aged Antibodies, Viral / immunology B-Lymphocyte Subsets / immunology B-Lymphocytes / immunology Basophils / immunology Betacoronavirus COVID-19 Case-Control Studies Cell Cycle Chemokine CXCL10 / immunology Chemokines / immunology Cohort Studies Coronavirus Infections / blood Cytokines / immunology Dendritic Cells / immunology Disease Progression Female Flow Cytometry Hospitalization Humans Immunologic Memory Immunophenotyping Interleukin-10 / immunology Interleukin-6 / immunology Leukocyte Count Lymphocyte Activation / immunology Male Middle Aged Pandemics Pneumonia, Viral / blood Prognosis SARS-CoV-2 Severity of Illness Index T-Lymphocyte Subsets / immunology T-Lymphocytes / immunology Up-Regulation

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
10 2020

Historique:

received: 06 06 2020

accepted: 27 07 2020

pubmed: 19 8 2020

medline: 23 10 2020

entrez: 19 8 2020

Statut: ppublish

Résumé

Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19.

Identifiants

DOI: 10.1038/s41591-020-1038-6 PMID: 32807934

pubmed: 32807934

doi: 10.1038/s41591-020-1038-6

pii: 10.1038/s41591-020-1038-6

doi:

Substances chimiques

Antibodies, Viral 0

CXCL10 protein, human 0

Chemokine CXCL10 0

Chemokines 0

Cytokines 0

IL10 protein, human 0

IL6 protein, human 0

Interleukin-6 0

Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1623-1635

Subventions

Organisme : Wellcome Trust (Wellcome)

ID : 106292/Z/4/Z

Pays : International

Organisme : National Institute for Academic Anaesthesia (NIAA)

ID : WKR0-2018-0047

Pays : International

Commentaires et corrections

Type : ErratumIn

Références

Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).

pubmed: 32015507 pmcid: 7095418

Yang, R., Gui, X. & Xiong, Y. Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. JAMA Netw. Open 3, e2010182 (2020).

pubmed: 32459353 pmcid: 7254178

Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501 (2020).

pubmed: 32473127 pmcid: 7237901

Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).

doi: 10.1056/NEJMoa2002032 pubmed: 32109013

Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature https://doi.org/10.1038/s41586-020-2380-z (2020).

Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

pubmed: 31986264 pmcid: 7159299

Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020).

pubmed: 32192578 pmcid: 7270045

Saif, L. J. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? Rev. Sci. Tech. 23, 643–660 (2004).

pubmed: 15702725

Docherty, A. B. et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. Brit. Med. J. 369, m1985 (2020).

pubmed: 32444460 pmcid: 7243036

Pan, D. et al. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. EClinicalMedicine 23 https://doi.org/10.1016/j.eclinm.2020.100404 (2020).

Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 5, eabd2071 (2020).

pubmed: 32591408 pmcid: 7319493

Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Preprint at bioRxiv https://doi.org/10.1101/2020.06.29.174888 (2020).

Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045 (2020).

pubmed: 32416070 pmcid: 7227586

Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 5, eabd7114 (2020).

pubmed: 32669287 pmcid: 7402634

Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA 117, 9490–9496 (2020).

pubmed: 32253318 pmcid: 7196837

Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473–474 (2020).

pubmed: 32303591

Wilson, J. G. et al. Cytokine profiling in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 140289 (2020).

Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N. Engl. J. Med. https://www.nejm.org/doi/10.1056/NEJMoa2021436 (2020).

Sobolev, O. et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17, 204–213 (2016).

pubmed: 26726811 pmcid: 6485475

Ghnewa, Y. G., Fish, M., Jennings, A., Carter, M. J. & Shankar-Hari, M. Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction. Med Klin. Intensivmed. Notfmed 115, 10–14 (2020).

pubmed: 32291506

Muñoz-Ruiz, M. et al. Tracking immunodynamics by identification of S-G(2)/M-phase T cells in human peripheral blood. J Autoimmun. https://doi.org/10.1016/j.jaut.2020.102466 (2020).

Simonetti, S. et al. Antigen-specific CD8

pubmed: 30488973 pmcid: 6850756

Pickering, S. et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. Preprint at medRxiv https://doi.org/10.1101/2020.06.02.20120345 (2020).

Abeler-Dörner, L. et al. High-throughput phenotyping reveals expansive genetic and structural underpinnings of immune variation. Nat. Immunol. 21, 86–100 (2020).

pubmed: 31844327

Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020).

pubmed: 32074444 pmcid: 7121626

Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).

pubmed: 32235945

Lafarge, X. et al. Cytomegalovirus infection in transplant recipients resolves when circulating γδ T lymphocytes expand, suggesting a protective antiviral role. J. Infect. Dis. 184, 533–541 (2001).

pubmed: 11494158

Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320, 1731–1735 (1989).

pubmed: 2543925

Luchsinger, L. L. et al. Serological analysis of New York City COVID19 convalescent plasma donors. Preprint at medRxiv https://doi.org/10.1101/2020.06.08.20124792 (2020).

Huang, K. J. et al. An interferon-γ-related cytokine storm in SARS patients. J. Med. Virol. 75, 185–194 (2005).

pubmed: 15602737

Shin, H.-S. et al. Immune responses to middle east respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin. Infect. Dis. 68, 984–992 (2019).

pubmed: 30060038

Dunning, J. et al. Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. Nat. Immunol. 19, 625–635 (2018).

pubmed: 29777224 pmcid: 5985949

Nizzoli, G. et al. Human CD1c

pubmed: 23794066

Kanodia, P. et al. Characterization of biological variation of peripheral blood immune cytome in an Indian cohort. Sci. Rep. 9, 14735 (2019).

pubmed: 31611580 pmcid: 6791881

Kwissa, M. et al. Dengue virus infection induces expansion of a CD14(

pubmed: 24981333 pmcid: 4116428

Ferreira da Mota, N. V. et al. Immunophenotyping of monocytes during human sepsis shows impairment in antigen presentation: a shift toward nonclassical differentiation and upregulation of FCγRi-receptor. Shock 50, 293–300 (2018).

pubmed: 29668526

Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55, 102763 (2020).

pubmed: 32361250 pmcid: 7165294

Chen, R. et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J. Allergy Clin. Immunol. 146, 89–100 (2020).

pubmed: 32407836 pmcid: 7212968

Cunha, B. A., Pherez, F. M. & Schoch, P. Diagnostic importance of relative lymphopenia as a marker of swine influenza (H1N1) in adults. Clin. Infect. Dis. 49, 1454–1456 (2009).

pubmed: 19824851

Mendes-Aguiar Cde, O. et al. The skin homing receptor cutaneous leucocyte-associated antigen (CLA) is up-regulated by Leishmania antigens in T lymphocytes during active cutaneous leishmaniasis. Clin. Exp. Immunol. 157, 377–384 (2009).

pubmed: 19664146

Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468 (2020).

pubmed: 32353859 pmcid: 7431030

Steinberg, E., Balakrishna, A., Habboushe, J., Shawl, A. & Lee, J. Calculated decisions: COVID-19 calculators during extreme resource-limited situations. Emerg. Med. Pr. 22, Cd1–cd5 (2020).

Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science eabc8511 (2020).

Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910–941 (2020).

pubmed: 32505227 pmcid: 7200337

Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 17, 533–535 (2020).

pubmed: 32203188 pmcid: 7091858

Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070–1076 (2020).

pubmed: 32514174 pmcid: 7382903

Guo, C. et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat. Commun. 11, 3924 (2020).

pubmed: 32764665 pmcid: 7413381

Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992–1000 (2020).

pubmed: 32320677 pmcid: 7172841

Ong, E. Z. et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe 27, 879–882 (2020).

pubmed: 32359396 pmcid: 7192089

Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727–11734 (2020).

pubmed: 32376634 pmcid: 7260975

Agrati, C. et al. V δ1 T lymphocytes expressing a Th1 phenotype are the major γδ T cell subset infiltrating the liver of HCV-infected persons. Mol. Med 7, 11–19 (2001).

pubmed: 11474123 pmcid: 1949990

Carsana, L. et al. Pulmonary post mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30434-5 (2020).

Crivellato, E., Travan, L. & Ribatti, D. Mast cells and basophils: a potential link in promoting angiogenesis during allergic inflammation. Int. Arch. Allergy Immunol. 151, 89–97 (2010).

pubmed: 19752562

Swystun, L. L. & Liaw, P. C. The role of leukocytes in thrombosis. Blood 128, 753–762 (2016).

pubmed: 27354721

Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part II: role in immunity. Front. Immunol. 6, 257 (2015).

pubmed: 26074922 pmcid: 4443744

Schaller, T. et al. Postmortem examination of patients with COVID-19. JAMA 323, 2518–2520 (2020).

pubmed: 32437497 pmcid: 7243161

Casrouge, A. et al. Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin. Exp. Immunol. 167, 137–148 (2012).

pubmed: 22132893 pmcid: 3248095

Ellinghaus, D. et al. Genomewide association study of severe COVID-19 with respiratory failure. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2020283 (2020).

Meyer, S. et al. AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell 166, 582–595 (2020).

Shankar-Hari, M. et al. Activation-associated accelerated apoptosis of memory B cells in critically Ill patients with sepsis. Crit. Care Med. 45, 875–882 (2017).

pubmed: 28296810